way back (February this year) i traded in ogxi, got in at the 9s and out before results were released. what a fiasco! that sp decline wasn't just a waterfall, or cliff, it's a chasm. business as usual for biotechs i guess.
anyways, during my thorough research the impression came over me that ogxi had a unique strategy. they licensed their less promising drug to teva, possibly hoping to keep apatorsen in house and profit from it exclusively. that obviously backfired. this is my favored hypothesis, since it's my opinion that the apatorsen target protein is much more central to cancer than hsp90.
so here are some positive thoughts:
significant increase in institutional holdership!!!! these are private funds as well, not market index buying
known side effect profile (though still quite onerous)
confirmed biological effect on cancer
can possibly overcome treatment resistance
apatorsen is in SEVEN p2 trials!
price veeeery low
does anyone else think going long ogxi now would be good idea? is anyone still following this stock??